Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Dec 27;13:244.
doi: 10.1186/1745-6215-13-244.

Impact of Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial

Affiliations
Free PMC article
Randomized Controlled Trial

Impact of Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial

Gilberto M Sperandio da Silva et al. Trials. .
Free PMC article

Abstract

Background: Pharmaceutical care is the direct interaction between pharmacist and patient, in order to improve therapeutic compliance, promote adequate pharmacotherapeutic follow-up, and improve quality of life. Pharmaceutical care may be effective in reducing complications and in improving the quality of life of patients with chronic diseases, like Chagas heart disease, while bringing a positive impact on health system costs. The morbidity and mortality indexes for patients with Chagas heart disease are high, especially if this heart disease is complicated by heart failure. In this setting, we hypothesize that pharmaceutical care might be an important tool for the clinical management of these patients by improving their quality of life, as a better compliance to their treatment and the avoidance and prompt correction of drug-related problems will minimize their symptoms, improve their functional class, and decrease the number of hospital admissions. Therefore, the aim of this trial is to evaluate the contribution of pharmaceutical care to clinical treatment of patients with Chagas heart disease complicated by heart failure.

Methods/design: A prospective, single-center randomized clinical trial will be conducted in patients with Chagas heart disease complicated by heart failure. A total of 88 patients will be randomly assigned into two parallel groups: an intervention group will receive standard care and pharmaceutical care, and a control group will receive only standard care. Both groups will be subjected to a follow-up period of 12 months. The primary outcome of this trial is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure Questionnaire. Secondary outcomes include drug-related problems, exercise tolerance as measured by the standard six-minute-walk test, and compliance.

Discussion: Patients with Chagas heart disease complicated by heart failure under pharmaceutical care are expected to improve their quality of life, present with a lower incidence of drug-related problems, improve their functional capacity, and improve in their compliance to treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT01566617.

Figures

Figure 1
Figure 1
General overview of study protocol. 6MWT, six-minute-walk test; DRPs, drug-related problems; HF, heart failure.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. World Health Organization. First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva: WHO Press; 2010.
    1. Ministry of Health Brazil. Plano Nacional de Saúde – PNS: 2012–2015. Brasília; 2011.
    1. Ministry of Health Brazil. Brazilian Consensus on Chagas Disease. Rev Soc Bras Med Trop. 2005;38:11–14. doi: 10.1590/S0037-86822005000100003. - DOI - PubMed
    1. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy – where do we stand after a hundred years? Prog Cardiovasc Dis. 2010;52:300–316. doi: 10.1016/j.pcad.2009.11.008. - DOI - PubMed
    1. Dias JC. The indeterminate form of human chronic Chagas’ disease. A clinical epidemiological review. Rev Soc Bras Med Trop. 1989;22:147–156. - PubMed

Publication types

MeSH terms

Substances

Associated data

Feedback